Table 6 Association between monocyte subsets at baseline and clinical outcome after ICI
Biomarker | NSCLC stage (n) | Treatment | Direction at baseline | Association with clinical outcome | Ref | |||
|---|---|---|---|---|---|---|---|---|
Response | PFS | OS | ||||||
Monocyte | CD69 MFI on intermediate monocytes | Resectable IIIA (n = 27) | Neoadjuvant αPD-1/chemo | ↑ | ↑ (p = 0.017) | [71] | ||
% CD14++CD16+CTLA4+ | Resectable IIIA (n = 27) | neoadjuvant αPD-1/chemo | ↓ | ↑ (p = 0.026) | ||||
CD33hi monocytes | III-IV (n = 26) | αPD-1 | ↑ | ↑ (p = 0.014) | [79] | |||
CD9+ non-classical monocytes | III-IV (n = 26) | αPD-1 | ↑ | ↑ (p = 0.012) | ||||
CD33 gMFI on CD14+ monocytes | III-IV (n = 26) | αPD-1 | ↑ | ↑ (p = 0.075) | ↑ (p = 0.006) | |||
PD-L1+ CD14+ monocytes | Advanced (n = 119) | αPD-1, αPD-L1, αPD-1/chemo, αPD-L1/chemo | ↑ | ↑ (p < 0.001) | ↑ (p = 0.02) | [95] | ||